These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 23721800)

  • 1. Targeting CD133 in an in vivo ovarian cancer model reduces ovarian cancer progression.
    Skubitz AP; Taras EP; Boylan KL; Waldron NN; Oh S; Panoskaltsis-Mortari A; Vallera DA
    Gynecol Oncol; 2013 Sep; 130(3):579-87. PubMed ID: 23721800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Aldehyde dehydrogenase in combination with CD133 defines angiogenic ovarian cancer stem cells that portend poor patient survival.
    Silva IA; Bai S; McLean K; Yang K; Griffith K; Thomas D; Ginestier C; Johnston C; Kueck A; Reynolds RK; Wicha MS; Buckanovich RJ
    Cancer Res; 2011 Jun; 71(11):3991-4001. PubMed ID: 21498635
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting tumor-initiating cancer cells with dCD133KDEL shows impressive tumor reductions in a xenotransplant model of human head and neck cancer.
    Waldron NN; Kaufman DS; Oh S; Inde Z; Hexum MK; Ohlfest JR; Vallera DA
    Mol Cancer Ther; 2011 Oct; 10(10):1829-38. PubMed ID: 21862685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CD133 expression defines a tumor initiating cell population in primary human ovarian cancer.
    Curley MD; Therrien VA; Cummings CL; Sergent PA; Koulouris CR; Friel AM; Roberts DJ; Seiden MV; Scadden DT; Rueda BR; Foster R
    Stem Cells; 2009 Dec; 27(12):2875-83. PubMed ID: 19816957
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A rational approach for cancer stem-like cell isolation and characterization using CD44 and prominin-1(CD133) as selection markers.
    Lee YJ; Wu CC; Li JW; Ou CC; Hsu SC; Tseng HH; Kao MC; Liu JY
    Oncotarget; 2016 Nov; 7(48):78499-78515. PubMed ID: 27655682
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Targeting cancer stem cells with an 131I-labeled anti-AC133 monoclonal antibody in human colorectal cancer xenografts.
    Lang J; Lan X; Liu Y; Jin X; Wu T; Sun X; Wen Q; An R
    Nucl Med Biol; 2015 May; 42(5):505-512. PubMed ID: 25669587
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Expressions of putative cancer stem cell markers ABCB1, ABCG2, and CD133 are correlated with the degree of differentiation of gastric cancer.
    Jiang Y; He Y; Li H; Li HN; Zhang L; Hu W; Sun YM; Chen FL; Jin XM
    Gastric Cancer; 2012 Oct; 15(4):440-50. PubMed ID: 22395309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. ARID3B increases ovarian tumor burden and is associated with a cancer stem cell gene signature.
    Roy L; Samyesudhas SJ; Carrasco M; Li J; Joseph S; Dahl R; Cowden Dahl KD
    Oncotarget; 2014 Sep; 5(18):8355-66. PubMed ID: 25327563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The utility and limitations of glycosylated human CD133 epitopes in defining cancer stem cells.
    Bidlingmaier S; Zhu X; Liu B
    J Mol Med (Berl); 2008 Sep; 86(9):1025-32. PubMed ID: 18535813
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A bispecific EpCAM/CD133-targeted toxin is effective against carcinoma.
    Waldron NN; Barsky SH; Dougherty PR; Vallera DA
    Target Oncol; 2014 Sep; 9(3):239-49. PubMed ID: 23900680
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identifying an ovarian cancer cell hierarchy regulated by bone morphogenetic protein 2.
    Choi YJ; Ingram PN; Yang K; Coffman L; Iyengar M; Bai S; Thomas DG; Yoon E; Buckanovich RJ
    Proc Natl Acad Sci U S A; 2015 Dec; 112(50):E6882-8. PubMed ID: 26621735
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells.
    Kryczek I; Liu S; Roh M; Vatan L; Szeliga W; Wei S; Banerjee M; Mao Y; Kotarski J; Wicha MS; Liu R; Zou W
    Int J Cancer; 2012 Jan; 130(1):29-39. PubMed ID: 21480217
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Expression of CD133 and CD117 in 64 Serous Ovarian Cancer Cases.
    Stemberger-Papić S; Vrdoljak-Mozetic D; Ostojić DV; Rubesa-Mihaljević R; Krigtofić I; Brncić-Fisher A; Kragević M; Eminović S
    Coll Antropol; 2015 Sep; 39(3):745-53. PubMed ID: 26898076
    [TBL] [Abstract][Full Text] [Related]  

  • 14. CD133+ tumor initiating cells in a syngenic murine model of pancreatic cancer respond to Minnelide.
    Banerjee S; Nomura A; Sangwan V; Chugh R; Dudeja V; Vickers SM; Saluja A
    Clin Cancer Res; 2014 May; 20(9):2388-99. PubMed ID: 24634377
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The role of CD133 expression in the carcinogenesis and prognosis of patients with lung cancer.
    Le H; Zeng F; Xu L; Liu X; Huang Y
    Mol Med Rep; 2013 Nov; 8(5):1511-8. PubMed ID: 24008862
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted inhibition of CD133+ cells in oral cancer cell lines.
    Damek-Poprawa M; Volgina A; Korostoff J; Sollecito TP; Brose MS; O'Malley BW; Akintoye SO; DiRienzo JM
    J Dent Res; 2011 May; 90(5):638-45. PubMed ID: 21220361
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting signal transducer and activator of transcription 3 pathway by cucurbitacin I diminishes self-renewing and radiochemoresistant abilities in thyroid cancer-derived CD133+ cells.
    Tseng LM; Huang PI; Chen YR; Chen YC; Chou YC; Chen YW; Chang YL; Hsu HS; Lan YT; Chen KH; Chi CW; Chiou SH; Yang DM; Lee CH
    J Pharmacol Exp Ther; 2012 May; 341(2):410-23. PubMed ID: 22328572
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Identification of cancer stem cells from human glioblastomas: growth and differentiation capabilities and CD133/prominin-1 expression.
    Gambelli F; Sasdelli F; Manini I; Gambarana C; Oliveri G; Miracco C; Sorrentino V
    Cell Biol Int; 2012 Jan; 36(1):29-38. PubMed ID: 21916848
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Inhibition of ataxia telangiectasia- and Rad3-related function abrogates the in vitro and in vivo tumorigenicity of human colon cancer cells through depletion of the CD133(+) tumor-initiating cell fraction.
    Gallmeier E; Hermann PC; Mueller MT; Machado JG; Ziesch A; De Toni EN; Palagyi A; Eisen C; Ellwart JW; Rivera J; Rubio-Viqueira B; Hidalgo M; Bunz F; Göke B; Heeschen C
    Stem Cells; 2011 Mar; 29(3):418-29. PubMed ID: 21308861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Isolation and propagation of a human CD133(-) colon tumor-derived cell line with tumorigenic and angiogenic properties.
    Navarro-Alvarez N; Kondo E; Kawamoto H; Hassan W; Yuasa T; Kubota Y; Seita M; Nakahara H; Hayashi T; Nishikawa Y; Hassan RA; Javed SM; Noguchi H; Matsumoto S; Nakaji S; Tanaka N; Kobayashi N; Soto-Gutierrez A
    Cell Transplant; 2010; 19(6):865-77. PubMed ID: 20587145
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.